Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients
| Autor: | Philipp Ivanyi, Christoph W. M. Reuter, Arnold Ganser, Stefan Brunotte, Paula Kappler, Michael A. Morgan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Science Urology Antineoplastic Agents Docetaxel Article Targeted therapy Prostate cancer Limit of Detection Soft tissue metastasis medicine Clinical endpoint Humans Testosterone Neoplasm Metastasis Aged Cancer Multidisciplinary Free testosterone Proportional hazards model business.industry Prostatic Neoplasms Prostate-Specific Antigen medicine.disease Prognosis Medicine business medicine.drug |
| Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021) Scientific Reports |
| ISSN: | 2045-2322 |
| Popis: | To date, only few data concerning the biologically active, free form of testosterone (FT) are available in metastatic prostate cancer (mPC) and its impact on disease, therapy and outcome is largely unknown. We retrospectively studied the effect of docetaxel on FT and total testosterone (TT) serum levels in 67 mPC patients between April 2008 and November 2020. FT and TT levels were measured before and weekly during therapy. The primary endpoint was overall survival (OS). Secondary endpoints were prostate-specific antigen and radiographic response (PSAR, RR), progression-free survival (PFS), FT/TT levels and safety. Median FT and TT serum levels were completely suppressed below the detection limit during docetaxel treatment (FT: from 0.32 pg/mL to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|